Nasal spray vaccine shows promise against childhood lung virus

NCT ID NCT06546423

First seen Apr 25, 2026 · Last updated May 16, 2026 · Updated 4 times

Summary

This study tested two experimental nasal spray vaccines designed to protect children against human metapneumovirus (HMPV) and parainfluenza virus type 3 (HPIV3), both of which can cause serious breathing problems. Twenty-four children aged 2 to 5 who already had antibodies to HPIV3 received either one of the vaccines or a placebo. The main goals were to see if the vaccines were safe and could trigger an immune response.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HUMAN METAPNEUMOVIRUS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • CIR - Rangos, Johns Hopkins Bloomberg School of Public Health

    Baltimore, Maryland, 21205, United States

  • CIR South

    Columbia, Maryland, 21045, United States

  • University of Rochester Medical Center

    Rochester, New York, 14642, United States

  • Vanderbilt University Medical Center

    Nashville, Tennessee, 37232, United States

Conditions

Explore the condition pages connected to this study.